Stock PHIL PHILOGEN S.P.A.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Philogen S.p.A.

Equities

PHIL

IT0005373789

Market Closed - Borsa Italiana
Other stock markets
 11:44:59 2024-05-31 am EDT 		5-day change 1st Jan Change
21.2 EUR +0.47% Intraday chart for Philogen S.p.A. +11.58% +14.59%
May. 30 Mib pegs 34,300; banking segment well AN
May. 30 Mib veers upward; ERG takes top spot AN

Summary

  • Overall, the company has poor fundamentals for a medium to long-term investment strategy.

Strengths

  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • Over the last twelve months, the sales forecast has been frequently revised upwards.
  • Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
  • For the past twelve months, EPS forecast has been revised upwards.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • Consensus analysts have strongly revised their opinion of the company over the past 12 months.
  • Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.

Weaknesses

  • As estimated by analysts, this group is among those businesses with the lowest growth prospects.
  • The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
  • The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
  • The company has insufficient levels of profitability.
  • Based on current prices, the company has particularly high valuation levels.
  • For the past year, analysts have significantly revised downwards their profit estimates.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

1st Jan change Capi. Investor Rating ESG Refinitiv
PHILOGEN S.P.A. Stock Philogen S.p.A.
+14.59% 926M -
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+11.91% 118B
B+
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+11.60% 106B
B+
BIONTECH SE Stock BioNTech SE
-4.68% 24.28B
B+
ARGENX SE Stock argenx SE
-0.82% 21.96B
B
GENMAB A/S Stock Genmab A/S
-10.12% 18.16B
A-
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-42.12% 16.37B
A-
BEIGENE, LTD. Stock BeiGene, Ltd.
-17.47% 15.56B
B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+2.77% 13.63B
C+
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+34.58% 12.27B
C+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
-
EV / Sales
Price to Book
-
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. PHIL Stock
  4. Ratings Philogen S.p.A.